MA34517B1 - Promédicaments comprenant un conjugué exendine-lieur - Google Patents

Promédicaments comprenant un conjugué exendine-lieur

Info

Publication number
MA34517B1
MA34517B1 MA35722A MA35722A MA34517B1 MA 34517 B1 MA34517 B1 MA 34517B1 MA 35722 A MA35722 A MA 35722A MA 35722 A MA35722 A MA 35722A MA 34517 B1 MA34517 B1 MA 34517B1
Authority
MA
Morocco
Prior art keywords
fragment
conjugate
prodrugs
relief
formula
Prior art date
Application number
MA35722A
Other languages
English (en)
Inventor
Felix Cleemann
Ulrich Hersel
Torben Lessmann
Harald Rau
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA34517B1 publication Critical patent/MA34517B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CETTE INVENTION CONCERNE UN PROMÉDICAMENT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI COMPRENANT UN CONJUGUÉ EXENDINE-LIEUR D-L, D REPRÉSENTANT UN FRAGMENT D'EXENDINE ; ET -L, UN FRAGMENT LIEUR BIOLOGIQUEMENT NON ACTIF -L1 REPRÉSENTÉ PAR LA FORMULE (I). DANS LA FORMULE (I), LA LIGNE EN POINTILLÉS INDIQUE LA LIAISON À L'UN DES GROUPES AMINÉS DU FRAGMENT EXENDINE PAR FORMATION D'UNE LIAISON AMIDE. CETTE INVENTION CONCERNE, EN OUTRE, DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LESDITS PROMÉDICAMENTS AINSI QUE LEUR UTILISATION EN TANT QUE MÉDICAMENT POUR TRAITER OU PRÉVENIR LES MALADIES OU LES TROUBLES QUI PEUVENT ÊTRE TRAITÉS PAR L'EXENDINE
MA35722A 2010-09-17 2011-09-16 Promédicaments comprenant un conjugué exendine-lieur MA34517B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10177327A EP2438930A1 (fr) 2010-09-17 2010-09-17 Promédicaments comprenant un conjugué de liaison d'exendine
PCT/EP2011/066097 WO2012035139A1 (fr) 2010-09-17 2011-09-16 Promédicaments comprenant un conjugué exendine-lieur

Publications (1)

Publication Number Publication Date
MA34517B1 true MA34517B1 (fr) 2013-09-02

Family

ID=43446651

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35722A MA34517B1 (fr) 2010-09-17 2011-09-16 Promédicaments comprenant un conjugué exendine-lieur

Country Status (30)

Country Link
US (1) US9133276B2 (fr)
EP (2) EP2438930A1 (fr)
JP (1) JP5932796B2 (fr)
KR (1) KR20130106820A (fr)
CN (1) CN103237561B (fr)
AR (1) AR082995A1 (fr)
AU (1) AU2011303823B2 (fr)
BR (1) BR112013006340A2 (fr)
CA (1) CA2811352C (fr)
CL (1) CL2013000716A1 (fr)
CO (1) CO6690765A2 (fr)
CY (1) CY1122226T1 (fr)
DK (1) DK2616102T3 (fr)
ES (1) ES2733734T3 (fr)
HR (1) HRP20191128T1 (fr)
HU (1) HUE044079T2 (fr)
IL (1) IL225127A (fr)
LT (1) LT2616102T (fr)
MA (1) MA34517B1 (fr)
MX (1) MX348983B (fr)
MY (1) MY158974A (fr)
NZ (1) NZ608387A (fr)
PH (1) PH12013500257A1 (fr)
PL (1) PL2616102T3 (fr)
PT (1) PT2616102T (fr)
RU (1) RU2593774C2 (fr)
SG (1) SG188197A1 (fr)
SI (1) SI2616102T1 (fr)
UY (1) UY33605A (fr)
WO (1) WO2012035139A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940803A1 (fr) * 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Lieur promedicament
AU2009209565B2 (en) * 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
CA2769162C (fr) * 2009-07-31 2017-12-05 Ascendis Pharma As Hydrogels insolubles dans l?eau a base de polyethylene glycol biodegradable
NZ597964A (en) 2009-07-31 2014-04-30 Sanofi Aventis Deutschland Long acting insulin composition
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
CA2849192C (fr) * 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention et traitement d'etats oculaires
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
WO2015086733A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
WO2015086728A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
CN104945499B (zh) * 2014-03-31 2019-12-10 博瑞生物医药（苏州）股份有限公司 结构修饰的glp-1类似物及其制备方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
AR105319A1 (es) * 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106554403B (zh) * 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
MY208384A (en) 2016-03-01 2025-05-05 Ascendis Pharma Bone Diseases As Pth prodrugs
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
US12453778B2 (en) 2016-09-29 2025-10-28 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release PTH compounds
KR102627405B1 (ko) 2016-09-29 2024-01-18 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
EP3335695B1 (fr) * 2016-12-15 2020-02-05 UPM-Kymmene Corporation Procédé de lyophilisation d'hydrogel comprenant de la cellulose nanofibrillaire, hydrogel therapeutique lyophilisé comprenant de la cellulose nanofibrillaire, et hydrogel comprenant de la cellulose nanofibrillaire
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico
EP3852786A4 (fr) 2018-09-19 2022-09-28 Georgia Tech Research Corporation Promédicament activé par protéase bactérienne à auto-dosage
MY209748A (en) 2019-02-11 2025-07-31 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN118184515A (zh) * 2024-03-06 2024-06-14 合肥微晶材料科技有限公司 一种耐湿热长适用期环氧固化剂的制备方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
AU673160B2 (en) 1992-02-28 1996-10-31 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999030727A1 (fr) 1997-12-17 1999-06-24 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
EP1054594B1 (fr) 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Effets inotropiques et diuretiques de l'exendine et du glp-1
WO2000021572A2 (fr) 1998-10-09 2000-04-20 The University Of Michigan Hydrogels et supports polymeres solubles dans l'eau pour administration de medicaments
JP2002531217A (ja) 1998-12-04 2002-09-24 チャンドラシェカー ピー． パサック， 生体適合性架橋ポリマー
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
DK1181323T3 (da) 1999-02-01 2011-10-17 Eidgenoess Tech Hochschule Biomaterialer dannet med nukleofil additionsreaktion med konjugerede uimættede grupper
CA2373680C (fr) 1999-05-17 2008-07-29 Conjuchem Inc. Protection de peptides therapeutiques endogenes contre l'activite peptidase par conjugaison de composants sanguins
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1223986A2 (fr) 1999-06-11 2002-07-24 Shearwater Corporation Hydrogels derives du chitosane et du poly(ethylene glycol)
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
BR0107942A (pt) 2000-01-28 2004-01-06 Infimed Therapeutics Inc Polìmeros de proteìna de liberação lenta
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (fr) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Prodrogues activables à séparateurs allongés et multiples
EP1423093A4 (fr) 2001-04-23 2005-11-30 Wisconsin Alumni Res Found Hydrogels modifies bifonctionnels
CZ20033182A3 (cs) 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
DE60132094T3 (de) 2001-10-26 2012-02-02 Octoplus Polyactive Sciences B.V. Verfahren zur Herstellung von gereinigten Partikeln
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003084926A2 (fr) 2002-04-04 2003-10-16 Enzon, Inc. Derives acyles polymeriques d'indoles
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
WO2003101425A2 (fr) 2002-06-03 2003-12-11 Alnis Biosciences, Inc. Articles polymeres contenant des agents therapeutiques
US20050164201A1 (en) 2002-06-10 2005-07-28 Harvey Diane M. Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses therof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004043493A1 (fr) 2002-11-14 2004-05-27 Syntarga B.V. Promedicaments conçus en tant qu'espaceurs de liberation multiple a elimination automatique
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
EP1525890A1 (fr) 2003-10-02 2005-04-27 Complex Biosystems GmbH Complexes protéine-protéophore
CA2940803A1 (fr) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Lieur promedicament
EP1586334A1 (fr) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugés avec PEG
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (fr) 2004-10-01 2006-04-13 Kyushu University, National University Corporation Cellule novatrice de production de stéroïde
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
US20090233841A1 (en) 2005-01-05 2009-09-17 Regents Of The University Of Minnesota Analgesic conjugates
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2007204815A1 (en) 2006-01-12 2007-07-19 Histogenics Corporation Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
DE602006007679D1 (de) 2006-03-31 2009-08-20 Sony Deutschland Gmbh Verfahren zur Herstellung eines vernetzten Polymer-Gels
WO2007140312A2 (fr) 2006-05-25 2007-12-06 The General Hospital Corporation Agents anti-réticulation et procédés permettant de bloquer la réticulation de préparations d'hydrogel injectables
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
AU2008214319A1 (en) * 2007-02-06 2008-08-14 Incept, Llc Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (fr) 2007-03-28 2008-10-02 Novo Nordisk A/S Composés peptidiques à pégylation biodégradable transitoire
DK2136850T3 (da) 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
CA2689909C (fr) 2007-06-08 2016-04-05 Ascendis Pharma As Conjugues polymeres transitoires longue duree de l'exendine
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
AU2009214615B2 (en) 2008-02-13 2014-06-12 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
NZ597964A (en) 2009-07-31 2014-04-30 Sanofi Aventis Deutschland Long acting insulin composition
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
CA2769162C (fr) 2009-07-31 2017-12-05 Ascendis Pharma As Hydrogels insolubles dans l?eau a base de polyethylene glycol biodegradable
JP5893566B2 (ja) 2009-10-29 2016-03-23 アセンディス ファーマ エー／エス 生分解性ヒドロゲルの滅菌
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine

Also Published As

Publication number Publication date
US20130189328A1 (en) 2013-07-25
SG188197A1 (en) 2013-04-30
CN103237561A (zh) 2013-08-07
MY158974A (en) 2016-11-30
MX348983B (es) 2017-07-06
CA2811352A1 (fr) 2012-03-22
IL225127A (en) 2017-07-31
MX2013002822A (es) 2013-04-05
CO6690765A2 (es) 2013-06-17
HUE044079T2 (hu) 2019-09-30
CL2013000716A1 (es) 2013-08-09
WO2012035139A1 (fr) 2012-03-22
DK2616102T3 (da) 2019-07-29
CA2811352C (fr) 2019-01-29
BR112013006340A2 (pt) 2020-08-04
HRP20191128T1 (hr) 2019-09-20
KR20130106820A (ko) 2013-09-30
US9133276B2 (en) 2015-09-15
PH12013500257A1 (en) 2017-01-25
PL2616102T3 (pl) 2019-10-31
EP2616102A1 (fr) 2013-07-24
AU2011303823B2 (en) 2014-07-17
UY33605A (es) 2012-04-30
RU2013117441A (ru) 2014-10-27
SI2616102T1 (sl) 2019-08-30
AR082995A1 (es) 2013-01-23
ES2733734T3 (es) 2019-12-02
PT2616102T (pt) 2019-08-01
LT2616102T (lt) 2019-07-25
CY1122226T1 (el) 2020-11-25
CN103237561B (zh) 2015-12-02
NZ608387A (en) 2015-04-24
AU2011303823A1 (en) 2013-04-04
JP5932796B2 (ja) 2016-06-08
RU2593774C2 (ru) 2016-08-10
EP2616102B1 (fr) 2019-05-01
EP2438930A1 (fr) 2012-04-11
JP2013538224A (ja) 2013-10-10

Similar Documents

Publication Publication Date Title
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
EP1848270A4 (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
WO2010115843A3 (fr) Composition pharmaceutique
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
WO2012080729A3 (fr) Inhibiteurs de caséine kinase 1δ (ck1δ)
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
WO2009106980A3 (fr) Dérivés d'indazole
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
WO2011026125A3 (fr) Compositions pharmaceutiques à rétention gastrique permettant une libération immédiate et prolongée d'acétaminophène
MY144132A (en) Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isoproproxypyridin)yl]-4-penten-2-amine
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
MA38190A2 (fr) Inhibiteurs d'autotaxine
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
FR2930552B1 (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
EP2321265A4 (fr) Dérivés d inositol et de tréhalose et compositions pharmaceutiques pour le traitement des maladies neurodégénératives comprenant ces dérivés
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation